JP6483336B2 - Hav検出 - Google Patents
Hav検出 Download PDFInfo
- Publication number
- JP6483336B2 JP6483336B2 JP2013254717A JP2013254717A JP6483336B2 JP 6483336 B2 JP6483336 B2 JP 6483336B2 JP 2013254717 A JP2013254717 A JP 2013254717A JP 2013254717 A JP2013254717 A JP 2013254717A JP 6483336 B2 JP6483336 B2 JP 6483336B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- primer
- hav
- target nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 114
- 108020004707 nucleic acids Proteins 0.000 claims description 82
- 102000039446 nucleic acids Human genes 0.000 claims description 82
- 239000000523 sample Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 38
- 230000003321 amplification Effects 0.000 claims description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 31
- 239000011541 reaction mixture Substances 0.000 claims description 30
- 239000012472 biological sample Substances 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 241000702617 Human parvovirus B19 Species 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 230000001351 cycling effect Effects 0.000 claims description 4
- 239000013615 primer Substances 0.000 description 92
- 108091034117 Oligonucleotide Proteins 0.000 description 45
- 241000709721 Hepatovirus A Species 0.000 description 35
- 230000002441 reversible effect Effects 0.000 description 19
- 241000700605 Viruses Species 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 230000003196 chaotropic effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 208000005252 hepatitis A Diseases 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000264368 Coptotermes lacteus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000589945 Magnetospirillum magnetotacticum Species 0.000 description 1
- 241000203367 Methanothermus fervidus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000042515 Tetraselmis rubens Species 0.000 description 1
- 241000191098 Thermoflexibacter ruber Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- -1 dNTPs Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本明細書中で用いる用語“富化する”は、標的核酸を含有する試料を処理するいずれかの方法であって、標的核酸を試料中に存在する他の物質の少なくとも一部から分離させる方法に関する。したがって、“富化”は、他の物質より多量の標的核酸を得ることと理解される。
配列依存性または生物特異的な方法、たとえば:
・アフィニティークロマトグラフィー
・固定化したプローブへのハイブリダイゼーション
配列非依存性または物理化学的な方法、たとえば:
・たとえばフェノール−クロロホルムによる液−液抽出
・たとえば純エタノールによる沈殿
・濾紙による抽出
・セチル−トリメチル−アンモニウム−ブロミドなどのミセル形成剤による抽出
・固定化したインターカレーション色素、たとえばアクリジン誘導体への結合
・シリカゲルまたは珪藻土への吸着
・カオトロピック条件下での磁性ガラス粒子(MGP)または有機シラン粒子への吸着
標的核酸を富化するための代表的方法は、Quiagenから市販されているPuregene−Kit(たとえば、注文番号158389)を用いる富化である。
・カオトロピック剤
・緩衝物質
・アルコール類
・還元剤
一般に溶液中の水分子の規則的構造ならびに分子内および分子間の非共有結合力を攪乱するカオトロピック剤は、試料調製操作に幾つか寄与することができる。特に、ただしそれだけではないが、それらはヌクレアーゼの三次元構造を攪乱することによるRNase阻害剤として適用できる。通常はそれ以上のRNase阻害剤をリシス用緩衝液に付与する必要はない。そのほかに、カオトロピック剤は生物膜、たとえば細胞膜、または細胞内器官が存在する場合にはそれらの膜の破壊に寄与する。また、それらは核酸がガラス(前記を参照)などの表面に粘着結合する際に重要な役割を果たすことができる。本発明に関するカオトロピック剤は、グアニジニウム塩、たとえばチオシアン酸グアニジニウムもしくは塩酸グアニジニウムもしくは塩化グアニジニウムもしくはイソチオシアン酸グアニジニウム、尿素、過塩素酸塩、たとえば過塩素酸カリウム、他のチオシアン酸塩、またはヨウ化カリウムである。ただし、他のカオトロピック剤も本発明の範囲において使用できる。
2種類のオリゴヌクレオチドセットの比較
HAVについて2種類のオリゴヌクレオチドセットを比較する並行した検出限界(LOD)試験を実施する。
増幅のために、下記の方法で2種類の試薬MMx R1およびMMx R2(R2−HAVまたはR2−HAVref)を混和し、単離された核酸と混合して、全反応体積50μlにする:
10μlのMMx R1試薬(3.3mMのMnOAc,pH6.1、および0.02%のナトリウムアジド,pH7.0)、15μlのMMx R2試薬(R2−HAVまたはR2−HAVref)、および25μlの単離された核酸を混和して、反応溶液を得る。
分析サイクラーの生データファイルを、自動ソフトウェアを用いて分析する。プロビット−用量応答ツールを用いてLODを決定する。計算したプロビットデータ(95%)を表2に挙げる。
Claims (12)
- 生物試料中のHAVを検出する方法であって、
a)HAVの核酸配列を含む標的核酸を反応混合物中で増幅する;その反応混合物は、標的核酸を含有する可能性のある生物試料、ならびに少なくとも第1および第2プライマーを含み、その際、第1プライマーの核酸配列はSEQ ID NO:7であり、第2プライマーの核酸配列はSEQ ID NO:11である;
その際、増幅によって増幅した標的核酸が生成する;そして
b)増幅した標的核酸を検出する
ことを含む前記方法。 - 増幅した標的核酸を工程a)の途中または後で検出する、請求項1に記載の方法。
- 反応混合物がさらに、増幅した標的核酸を検出するためのプローブを含む、請求項1または2に記載の方法。
- プローブの核酸配列がSEQ ID NO:13〜14から選択される、請求項3に記載の方法。
- 第2標的核酸を、HAVと並行して、HAVを含まない別のバイアル内において同じサイクリング条件下で同じ割合の増幅試薬を含む反応混合物中で検出する、請求項1〜4のいずれか1項に記載の方法。
- 第1プライマーおよび第2プライマーを含み、第1プライマーの核酸配列はSEQ ID NO:7であり、第2プライマーの核酸配列はSEQ ID NO:11である、HAVを検出するための反応混合物。
- 第1および第2プライマーならびにプローブを含み、第1プライマーの核酸配列はSEQ ID NO:7であり、第2プライマーの核酸配列はSEQ ID NO:11であり、プローブの核酸配列はSEQ ID NO:13〜14から選択される、HAVを検出するための反応混合物。
- ポリメラーゼ、ヌクレオチド、ならびに請求項6に記載の第1プライマーおよび第2プライマーを含む、HAVを検出するためのキット。
- さらにプローブを含み、プローブの核酸配列がSEQ ID NO:13〜14から選択される、請求項8に記載のキット。
- さらに、生物試料中の第2標的核酸を反応混合物中で増幅および検出する、請求項1に記載の方法。
- 第2標的核酸がパルボウイルスB19である、請求項10に記載の方法。
- プローブの核酸配列がSEQ ID NO:14である、請求項3に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261736686P | 2012-12-13 | 2012-12-13 | |
US61/736,686 | 2012-12-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014121320A JP2014121320A (ja) | 2014-07-03 |
JP6483336B2 true JP6483336B2 (ja) | 2019-03-13 |
Family
ID=48047898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013254717A Active JP6483336B2 (ja) | 2012-12-13 | 2013-12-10 | Hav検出 |
Country Status (4)
Country | Link |
---|---|
US (2) | US10100374B2 (ja) |
EP (1) | EP2743355B1 (ja) |
JP (1) | JP6483336B2 (ja) |
CN (1) | CN103866045B (ja) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3427993A (en) * | 1991-12-23 | 1993-07-28 | Chiron Corporation | HAV probes for use in solution phase sandwich hybridization assays |
EP0590327B1 (en) * | 1992-09-11 | 2003-04-09 | F. Hoffmann-La Roche Ag | Detection of nucleic acids in blood |
KR100419842B1 (ko) * | 2001-04-10 | 2004-02-25 | 부광약품 주식회사 | 한국에서 분리한 신규한 에이형 간염바이러스 뉴클레오티드 서열 |
CA2489346C (en) | 2002-06-12 | 2015-07-14 | Chiron Corporation | Identification of oligonucleotides for the capture, detection and quantitation of hepatitis a viral nucleic acid |
ES2422583T3 (es) | 2004-02-10 | 2013-09-12 | Hoffmann La Roche | Detección de parvovirus B19 |
JP4753943B2 (ja) * | 2004-07-13 | 2011-08-24 | ジェン−プローブ・インコーポレーテッド | A型肝炎ウイルス核酸の検出のための組成物及び方法 |
AU2007353946A1 (en) | 2007-06-01 | 2008-12-04 | Universidad De Barcelona | Standardized method and kit for the quantification of hepatitis A virus |
JP4447643B2 (ja) | 2008-04-15 | 2010-04-07 | 株式会社ヨシカワ | 粉粒体供給機 |
CN101660005B (zh) * | 2009-07-24 | 2011-08-31 | 广州华峰生物科技有限公司 | 基于环介导等温扩增技术的甲型肝炎病毒基因快速诊断试剂盒及其检测方法 |
KR101338292B1 (ko) * | 2009-11-13 | 2013-12-09 | 중앙대학교 산학협력단 | A형 간염 바이러스에 대한 역전사 중합효소 연쇄반응 효소면역 측정법 |
US9725754B2 (en) | 2010-07-29 | 2017-08-08 | Sean F. Boyle | Generic sample preparation |
BR112013031802A2 (pt) * | 2011-09-07 | 2016-12-20 | Grifols Therapeutics Inc | molécula de ácido nucleico isolada, composição, métodos para a amplificação de uma sequência alvo, e para a determinação de hav em uma amostra, e, kit |
-
2013
- 2013-04-09 EP EP13162833.1A patent/EP2743355B1/en active Active
- 2013-11-22 US US14/088,007 patent/US10100374B2/en active Active
- 2013-12-10 JP JP2013254717A patent/JP6483336B2/ja active Active
- 2013-12-13 CN CN201310732891.5A patent/CN103866045B/zh active Active
-
2018
- 2018-09-06 US US16/123,277 patent/US10865454B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10100374B2 (en) | 2018-10-16 |
CN103866045A (zh) | 2014-06-18 |
CN103866045B (zh) | 2020-06-23 |
EP2743355A1 (en) | 2014-06-18 |
US20190010562A1 (en) | 2019-01-10 |
US20140170638A1 (en) | 2014-06-19 |
US10865454B2 (en) | 2020-12-15 |
JP2014121320A (ja) | 2014-07-03 |
EP2743355B1 (en) | 2016-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muir et al. | Rapid diagnosis of enterovirus infection by magnetic bead extraction and polymerase chain reaction detection of enterovirus RNA in clinical specimens | |
ES2439951T3 (es) | Detección y cuantificación multiplex de ácidos nucleicos microbianos controlada de forma interna | |
Mohamed et al. | A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA | |
US7714122B2 (en) | Nucleic acid molecules and kits including VP1 and VP3 nucleic acid molecules, useful for detecting and identifying enteroviruses | |
US9416398B2 (en) | Generic buffer for amplification | |
JP5992909B2 (ja) | 微生物核酸の定性的および定量的検出 | |
CN103703148B (zh) | 在单路或多路测定法中用于检测人细小病毒核酸和用于检测甲型肝炎病毒核酸的组合物和方法 | |
JP7105553B2 (ja) | ターゲット核酸検出のための二重プローブアッセイ | |
ES2644949T3 (es) | Oligonucleótidos para controlar la amplificación de ácidos nucleicos | |
JP2001501822A (ja) | 非ポリオエンテロウィルスの検出および同定 | |
Archimbaud et al. | Improved diagnosis on a daily basis of enterovirus meningitis using a one‐step real‐time RT‐PCR assay | |
TW201245452A (en) | Nucleic acid detection | |
EP1583556A1 (en) | Sequences diagnostic for foot and mouth disease | |
RU2524115C2 (ru) | Способ специфичной детекции малопредставленных фракций рнк в в биологическом образце | |
JP6483336B2 (ja) | Hav検出 | |
JP4388061B2 (ja) | E型肝炎ウイルスを検出するためのlamp増幅用核酸プライマーセット | |
JP7385471B2 (ja) | Phi6内部対照組成物、装置、および方法 | |
JP6121591B2 (ja) | 微生物核酸の定性的および定量的検出 | |
JPH03117499A (ja) | ウイルスを特徴づける方法 | |
Poh et al. | Detection of enteroviruses from clinical specimens | |
Patel et al. | Development of a simple restriction fragment length polymorphism assay for subtyping of coxsackie B viruses | |
Gartzonika et al. | Evaluation of a commercially available reverse transcription-PCR enzyme immunoassay (Enterovirus Consensus kit) for the diagnosis of enterovirus central nervous system infections | |
Tracy et al. | Detection of human enteroviruses using the polymerase chain reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160815 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180323 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180625 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6483336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |